Literature DB >> 28270736

Trastuzumab in metastatic breast cancer after complete remission: an expensive commitment for an entire life?

D Bernardi1, M Stefani1, M Boccalon1, C Raiti1.   

Abstract

Entities:  

Year:  2017        PMID： 28270736      PMCID： PMC5330644          DOI： 10.3747/co.24.3413

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  5 in total

1.  Trastuzumab in metastatic breast cancer after complete remission: How long is enough?

Authors:  Arzu Oguz; Samed Rahatli; Ozden Altundag; Kadri Altundag
Journal:  Med Oncol       Date:  2015-06-30       Impact factor: 3.064

2.  Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.

Authors:  Filippo Montemurro; Aleix Prat; Valentina Rossi; Giorgio Valabrega; Jeff Sperinde; Caterina Peraldo-Neia; Michela Donadio; Patricia Galván; Anna Sapino; Massimo Aglietta; José Baselga; Maurizio Scaltriti
Journal:  Mol Oncol       Date:  2013-09-13       Impact factor: 6.603

3.  Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab.

Authors:  B Yeo; K Kotsori; K Mohammed; G Walsh; I E Smith
Journal:  Breast       Date:  2015-10-09       Impact factor: 4.380

4.  Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.

Authors:  Debu Tripathy; Dennis J Slamon; Melody Cobleigh; Andrew Arnold; Mansoor Saleh; Joanne E Mortimer; Maureen Murphy; Stanford J Stewart
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

5.  Prolonged complete response after treatment withdrawal in HER2-overexpressed, hormone receptor-negative breast cancer with liver metastases: the prospect of disappearance of an incurable disease.

Authors:  Erika Viel; Flavie Arbion; Catherine Barbe; Philippe Bougnoux
Journal:  BMC Cancer       Date:  2014-09-22       Impact factor: 4.430
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.